Peptide therapy claims on TikTok: what the science actually supports

What did @daviddemesquita actually say?

The creator made a clear, confident argument: myostatin inhibitors like follistatin and ACE-031 are expensive, and more importantly, they don't work in humans. He said follistatin is "never shown in humans to actually be effective" while being effective in rats, and dismissed ACE-031 as prohibitively costly despite having some human research behind it. He also shared personal experience, saying he ran these compounds himself and saw "zero results."

This is a more nuanced take than you usually see in peptide content, which tends toward hype. He's skeptical of his own community's enthusiasm, and that's worth acknowledging. But his summary is a mix of accurate science and some oversimplification that deserves a closer look.

Does the science back this up?

On follistatin specifically, he's largely correct. Human data is sparse and unconvincing. A 2015 study by Rodino-Klapac et al. published in Molecular Therapy looked at follistatin gene therapy in Becker muscular dystrophy patients and found modest functional improvements, but this was gene therapy delivery, not injected peptide, and it was a very small trial. No well-controlled human study has demonstrated that subcutaneous or intramuscular injection of follistatin protein produces meaningful muscle hypertrophy in healthy adults.

The rat data is genuinely striking. Lee and McPherron published foundational work in Nature as far back as 1997 showing myostatin knockout produced dramatic muscle overgrowth in mice. Follistatin overexpression studies in rodents have replicated this. But the translation gap between rodent myostatin biology and human physiology is real. Humans don't respond the same way, and the peptide stability and delivery challenges are significant.

ACE-031, a fusion protein that acts as a decoy receptor for myostatin and related ligands, does have human trial data. Attie et al. (2013, Muscle and Nerve) ran a Phase 2 trial in healthy postmenopausal women and showed increased lean mass and decreased fat mass. That's real human evidence. The creator says he believes human research backs ACE-031, and he's right to say so.

What did they get wrong (or right)?

He got the follistatin skepticism right. Calling injected follistatin a waste of money for muscle building in healthy humans is a defensible position given current evidence. Personal anecdote isn't data, but it aligns with what the clinical literature suggests.

Where he oversimplifies: ACE-031 isn't just expensive, it was also halted in clinical trials due to safety concerns. Acceleron Pharma stopped trials after adverse events including nosebleeds and gum bleeding, likely linked to effects on other TGF-beta family members beyond myostatin. Saying ACE-031 is just "stupid expensive" misses this. The cost problem is real, but the safety signal is the more important reason a healthy person should not be self-administering this compound.

He also doesn't mention that the entire myostatin inhibitor category has struggled in late-stage clinical trials even in disease populations. Stamulumab, an anti-myostatin antibody, failed to show significant benefit in muscular dystrophy trials (Wagner et al., 2008, Annals of Neurology). This is a consistent pattern, not just a follistatin problem.

What should you actually know?

The honest summary here: the idea of blocking myostatin to build muscle is scientifically legitimate in theory. The biology is real. What hasn't held up is the practical execution of getting these compounds into humans in a form that actually works at a dose that's safe and affordable.

• Follistatin injections sold in the peptide market are not the same as the gene therapy vectors used in academic trials. What you're buying is not what was studied.
• ACE-031 had a real clinical signal but real safety concerns. It is not a compound to self-administer based on price optimization logic.
• No myostatin inhibitor is currently approved by the FDA for muscle building in healthy adults. Any compound you find sold online exists outside regulatory oversight.
• The translation gap between rodent myostatin biology and human outcomes has been a consistent theme across multiple pharmaceutical programs with far more resources than any individual experimenter.
• If you're looking at this category for legitimate therapeutic reasons, that's a conversation for a clinician, not a TikTok protocol.

The creator's instinct to push back on community hype here is reasonable. But the safety dimension of ACE-031 deserved more than a price objection.